Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.62 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.62 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.62 |
| ▸ | ABHD6 | Q9BV23 | 8/20 | 0.50 |
| ▸ | TRAP1 | Q12931 | 5/20 | 0.45 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427494 | 0.86 | DPP8 (0.57) | DPP8DPP9DPP7ABHD6TRAP1 | |
| SCHEMBL8422243 | 0.82 | DPP8 (0.59) | DPP8DPP9DPP7ABHD6TRAP1 | |
| SCHEMBL6886590 | 0.79 | DPP8 (0.54) | DPP8DPP9DPP7ABHD6TRAP1 | |
| SCHEMBL3478866 | 0.77 | DPP8 (0.60) | DPP8DPP9DPP7ABHD6TRAP1 | |
| SCHEMBL8083813 | 0.77 | DPP8 (0.67) | DPP8DPP9DPP7ABHD6TRAP1 | |
| SCHEMBL7454462 | 0.76 | ABHD6 (0.61) | ABHD6 | |
| SCHEMBL8404042 | 0.75 | NOTUM (0.61) | DPP8DPP9DPP7ABHD6TRAP1 | |
| SCHEMBL8221404 | 0.75 | DDB1 (0.55) | DPP8DPP9DPP7ABHD6TRAP1 | |
| SCHEMBL3055486 | 0.74 | TRAP1 (0.56) | DPP8DPP9DPP7ABHD6TRAP1 | |
| SCHEMBL497487 | 0.74 | TRAP1 (0.56) | DPP8DPP9DPP7ABHD6TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582605-B2 | Phosphorus-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080039375-A1 | Phosphorus-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039375-A1 | Phosphorus-containing hepatitis C serine protease inhibitors | PRSS1, PPP4C, G6PC1 | DPP8 123/4885DPP9 162/4885DPP7 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.